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Background
Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus 
(HIV) infection may delay disease progression but has not been adequately evaluated.
Methods
We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART 
for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months 
after seroconversion. The primary end point was a CD4+ count of less than 350 cells 
per cubic millimeter or long-term ART initiation.
Results
A total of 366 participants (60% men) underwent randomization to 48-week ART 
(123 participants), 12-week ART (120), or standard care (123), with an average follow-
up of 4.2 years. The primary end point was reached in 50% of the 48-week ART 
group, as compared with 61% in each of the 12-week ART and standard-care groups. 
The average hazard ratio was 0.63 (95% confidence interval [CI], 0.45 to 0.90; 
P = 0.01) for 48-week ART as compared with standard care and was 0.93 (95% CI, 
0.67 to 1.29; P = 0.67) for 12-week ART as compared with standard care. The propor-
tion of participants who had a CD4+ count of less than 350 cells per cubic millime-
ter was 28% in the 48-week ART group, 40% in the 12-week group, and 40% in the 
standard-care group. Corresponding values for long-term ART initiation were 22%, 
21%, and 22%. The median time to the primary end point was 65 weeks (95% CI, 
17 to 114) longer with 48-week ART than with standard care. Post hoc analysis 
identified a trend toward a greater interval between ART initiation and the primary 
end point the closer that ART was initiated to estimated seroconversion (P = 0.09), 
and 48-week ART conferred a reduction in the HIV RNA level of 0.44 log10 copies 
per milliliter (95% CI, 0.25 to 0.64) 36 weeks after the completion of short-course 
therapy. There were no significant between-group differences in the incidence of the 
acquired immunodeficiency syndrome, death, or serious adverse events.
Conclusions
A 48-week course of ART in patients with primary HIV infection delayed disease 
progression, although not significantly longer than the duration of the treatment. 
There was no evidence of adverse effects of ART interruption on the clinical out-
come. (Funded by the Wellcome Trust; SPARTAC Controlled-Trials.com number, 
ISRCTN76742797, and EudraCT number, 2004-000446-20.)
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A lthough the use of highly active antiretroviral therapy (ART) in human im-munodeficiency virus (HIV) disease reduc-
es morbidity and mortality,1-3 the role of ART in 
the management of primary HIV infection remains 
controversial.4-6 Immunologic damage after HIV 
acquisition occurs rapidly and is not wholly re-
versible by later ART.7-9 Observational studies have 
suggested that a short course of ART during pri-
mary HIV infection may preserve immune func-
tion,10,11 decrease viral evolution,12 and limit the 
viral reservoir.13-15
Two randomized, controlled trials — the AIDS 
Clinical Trials Group Setpoint Study and the 
Primo-SHM trial, involving 130 and 115 partici-
pants, respectively — were designed to evaluate 
the effect of short-course ART versus no therapy 
on HIV RNA levels and showed modest delays in 
the initiation of long-term ART and a transient 
lowering of the viral set point.16,17 However, 
there is currently no evidence from randomized 
trials on whether initiating ART during primary 
HIV infection delays disease progression.
The Short Pulse Anti-Retroviral Therapy at Sero-
conversion (SPARTAC) trial was designed to de-
termine whether short-term ART during primary 
HIV infection can lengthen the time until patients 
reach a CD4+ count of less than 350 cells per 
cubic millimeter or require long-term ART.
Me thods
Study Design and Participants
The SPARTAC trial was an open-label, randomized, 
controlled trial that enrolled adults with primary 
HIV infection from August 2003 through July 
2007 in eight countries. Primary HIV infection 
was defined as infection meeting one or more of 
the following criteria: a positive HIV-antibody test 
within 6 months after a negative test (criterion 
1), a negative HIV-antibody test with a positive 
reverse-transcription–polymerase-chain-reaction 
assay for HIV RNA (criterion 2), a low level of HIV 
antibodies (optical density units [OD], <0.6) accord-
ing to a serologic testing algorithm for recent 
infection (subtype B strain only)18 (criterion 3), an 
equivocal HIV-antibody test with a repeat test with-
in 2 weeks showing an increase in the level of 
HIV antibodies (criterion 4), or clinical manifes-
tations of symptomatic HIV seroconversion illness 
supported by antigen positivity and less than 4 pos-
itive bands on Western blot analysis (criterion 5).
Eligible participants underwent randomization 
within 6 months after the antibody test showing 
negative results, equivocal results, or a low anti-
body level. Persons in whom ART was indicated 
were ineligible. All participants gave written in-
formed consent; the trial was approved by research 
ethics committees in each country.
The time of seroconversion was estimated as 
the midpoint between the most recent negative 
or equivocal test and the first positive test for 
patients who met criterion 1 or 4; as the date 
of the test for patients who met criterion 2, 3 
(if OD ≤0.01), or 5; and as the date of the test 
− [(OD × 150) ÷ 2] days for patients who met criteri-
on 3 if the antibody level was greater than 0.01 OD.
Study Oversight
An independent data and safety monitoring com-
mittee reviewed interim data annually (five times 
in total) with the use of Haybittle–Peto criteria to 
guide recommendations for stopping the study 
or modifying the protocol. The study was funded 
by the Wellcome Trust, and Imperial College, 
London, was the sponsor; Abbott Laboratories 
provided lopinavir–ritonavir (Kaletra and Aluvia) 
for the African sites. None of those bodies had 
any role in the trial design; the collection, analy-
sis, or interpretation of the data; or the writing of 
the manuscript. The trial writing group vouches 
for the accuracy and completeness of the data 
presented and for the fidelity of this report to the 
study protocol, which is available with the full 
text of this article at NEJM.org.
Randomization and Follow-up
Participants were randomly assigned, in a 1:1:1 ra-
tio, to receive ART for 48 weeks, ART for 12 weeks, 
or no therapy (standard of care), in blocks of ran-
domly varying size and with stratification accord-
ing to country and evidence of HIV seroconver-
sion (categorized as definitive [criterion 1 or 2] 
or presumptive [any other criterion]).
The intended treatment regimen was chosen by 
the treating clinician before randomization; two 
nucleoside reverse-transcriptase inhibitors (NRTIs) 
plus a ritonavir-boosted protease inhibitor were 
recommended, to avoid the risk of resistance to 
nonnucleoside reverse-transcriptase inhibitors 
(NNRTIs) on stopping owing to their differen-
tial clearance19,20 and to avoid the increased risk 
of rash with NNRTIs21 (rash is already common 
in primary HIV infection). Long-term ART was 
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administered according to local HIV treatment 
guidelines or at the discretion of the treating 
clinician.
Clinic visits were scheduled at weeks 0, 4, 12, 
16, and 24, and every 12 weeks thereafter. Follow-
up was planned until the 360th enrolled partici-
pant had completed 3.5 years, which occurred on 
November 7, 2010; participants not seen on or 
after this date were considered lost to follow-up. 
End Points
The primary end point was a composite of a CD4+ 
count of less than 350 cells per cubic millimeter 
(documented >3 months after randomization and 
confirmed within 4 weeks) or initiation of long-
term ART. Secondary end points included the 
separate components of the primary end point, 
the acquired immunodeficiency syndrome (AIDS) 
or death, HIV-specific CD4+ and CD8+ respons-
es at week 60, the slope of decline in the CD4+ 
count from 24 weeks after ART interruption in the 
treatment groups as compared with the slope of 
decline from randomization in the standard-care 
group, the development of drug resistance not 
present at baseline by week 120, changes in blood 
pressure from randomization to weeks 12 and 
48, and virologic failure of the first long-term 
ART regimen (HIV RNA level, >400 copies per 
milliliter). We also examined changes in the 
CD4+ count and HIV RNA level over time. For 
full details of the study design, see the protocol 
and the statistical analysis plan, available at 
NEJM.org.
Procedures
The lower limit of detection for the plasma HIV 
RNA level was 50 copies per milliliter, except in 
South Africa and Uganda (400 copies per milliliter). 
Clinical AIDS events excluded a CD4+ count of 
less than 200 cells per cubic millimeter. Serious 
adverse events, deaths, and AIDS events were re-
viewed by two clinicians (one independent) who 
were not aware of the study-group assignments.
To determine whether there was new drug re-
sistance by week 120, viral sequencing was per-
formed at baseline, 4 weeks after the interrup-
tion of ART in the treatment groups, and at the 
last time point, up to 120 weeks, at which the 
virus was detectable (≥50 copies per milliliter) in 
participants receiving long-term ART. Resistance 
mutations were classified according to the algo-
rithm used by the Stanford University HIV Drug 
Resistance Database, and HIV subtype was deter-
mined according to the Rega Institute system22 
in March and April 2011.
An interferon-γ enzyme-linked immunosorbent 
spot (ELISpot) assay23 was used to measure HIV 
type 1–specific CD8+ responses across Gag over-
lapping peptides in all participants with the sub-
type B strain of HIV; CD4+ responses were also 
measured in U.K. participants with subtype B. 
All assays were performed in duplicate.
Statistical Analysis
On the basis of data from the CASCADE (Con-
certed Action on Seroconversion to AIDS and 
Death in Europe) study,24 we calculated that we 
would need to enroll 360 patients in order to pro-
vide 90% power to detect a relative reduction in 
the risk of progression to the original primary 
end point (a CD4+ count of <350 cells per cubic 
millimeter) of 50% with 48-week ART and 25% 
with 12-week ART, as compared with standard 
care, at a significance level of 5%. We assumed a 
recruitment period of 18 months, a minimum of 
3.5 years of follow-up, and a 10% rate of loss to 
follow-up.
The time to the primary end point and other 
time-to-event end points was estimated with the 
use of Kaplan–Meier plots, and differences be-
tween groups were summarized by means of 
average hazard ratios that were estimated with 
the use of proportional-hazards models (adjust-
ed for randomization stratification factors), with 
the two components of the primary end point 
also considered as competing risks. Categorical 
outcomes were compared between groups with 
the use of chi-square tests and logistic-regression 
models, and continuous outcomes were com-
pared with the use of linear regression, with 
adjustment for baseline values. Slopes of decline 
in the CD4+ count were modeled with the use of 
linear mixed models. Average CD4+ counts and 
HIV RNA levels were estimated with the use of 
a time-averaged area-under-the-curve analysis. 
Analyses were performed on an intention-to-
treat basis.
R esult s
Baseline Characteristics of the Participants
Of 371 participants who underwent randomiza-
tion, 5 met major ineligibility criteria and were 
excluded from all analyses, as specified by the 
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statistical analysis plan (Fig. 1). Of the remaining 
366 participants (123 in the 48-week ART group, 
120 in the 12-week ART group, and 123 in the 
standard-care group), 246 (67%) and 9 (2%) were 
eligible under definitive criteria 1 and 2, respec-
tively, and 72 (20%), 1 (0.3%), and 38 (10%) were 
eligible under presumptive criteria 3, 4, and 5, re-
spectively. Nine participants had Fiebig stage I 
infection (acquired during the past several days), 
and the remainder had stage V or VI infection 
(positive HIV-antibody test).25
The characteristics of the participants were 
balanced across the study groups (Table 1). The 
majority of participants were men infected through 
sex between men (205 participants [56%]) and 
women infected through sex with men (146 par-
ticipants [40%]). The median interval between 
seroconversion and randomization was 12 weeks 
(interquartile range, 9 to 15), the median base-
line CD4+ count was 559 cells per cubic milli-
meter (interquartile range, 435 to 700), and the 
median plasma HIV RNA level was 4.53 log10 
copies per milliliter (interquartile range, 3.67 to 
5.18). Of the 364 participants for whom infor-
mation about the subtype strain was available, 
208 (57%) and 120 (33%) were infected with HIV 
subtypes B and C, respectively, and 21 (6%) had 
evidence of transmitted drug-resistant virus.
Follow-up
The median follow-up was 4.2 years (interquar-
tile range, 3.7 to 4.7), and an average of 89% of 
scheduled visits were attended, a rate that was 
balanced across the groups. A total of 46 partici-
pants (13%) were lost to follow-up for the pri-
mary end-point analysis (15% of the 48-week 
ART group, 9% of the 12-week ART group, and 
14% of the standard-care group), although 26 of 
these participants (57%) had been assessed for 
the primary end point in the previous month.
All but 5 participants who were randomly as-
signed to ART started therapy (all 5 were in the 
48-week ART group), with more than 99% ini-
tiating therapy in 14 days or less and 93% in 
3 days or less after randomization; 91% received 
an initial regimen of two NRTIs and a ritonavir-
boosted protease inhibitor.
Primary End Point
A total of 209 participants reached the primary 
end point (61 in the 48-week ART group [50%], 
73 in the 12-week ART group [61%], and 75 in the 
standard-care group [61%]) (Fig. 2A). Of these 
participants, 130 had a confirmed CD4+ count of 
less than 350 cells per cubic millimeter (34 in the 
48-week ART group, 48 in the 12-week ART 
group, and 48 in the standard-care group), and 
79 started long-term ART without a confirmed 
CD4+ count of less than 350 cells per cubic mil-
limeter (27 in the 48-week ART group, 25 in the 
12-week ART group, and 27 in the standard-care 
group). The hazard ratio for the primary end 
point with 48-week ART as compared with stan-
dard care was 0.63 (95% confidence interval [CI], 
0.45 to 0.90; P = 0.01), and the hazard ratio with 
12-week ART as compared with standard care 
was 0.93 (95% CI, 0.67 to 1.29; P = 0.67).
Median times to the primary end point were 
222 weeks in the 48-week ART group (95% CI, 
189 to 270), 184 weeks in the 12-week ART group 
(95% CI, 140 to 214), and 157 weeks in the 
standard-care group (95% CI, 114 to 213). The 
difference between the 48-week ART group and 
the standard-care group was 65 weeks (95% CI, 
17 to 114), which was not significantly longer than 
the duration of the treatment (48 weeks). The 
difference between the 12-week ART group and 
the standard-care group was 27 weeks (95% CI, 
−25 to 79).
With the two components of the primary end 
point analyzed as competing risks, the cumula-
tive probability of a confirmed CD4+ count of 
less than 350 cells per cubic millimeter by 4 
years was 0.27 in the 48-week ART group (95% 
CI, 0.19 to 0.35), 0.38 in the 12-week ART group 
(95% CI, 0.29 to 0.47), and 0.39 in the standard-
care group (95% CI, 0.31 to 0.48) (Fig. 2B); the 
corresponding values for long-term ART initia-
tion were 0.17 (95% CI, 0.11 to 0.24), 0.19 (95% 
CI, 0.12 to 0.26), and 0.18 (95% CI, 0.12 to 0.26) 
(Fig. 2C). We found no evidence of a different 
Figure 1 (facing page). Study Enrollment, Randomization, 
and Outcomes.
The primary end point was a confirmed CD4+ count of 
less than 350 cells per cubic millimeter or the initiation 
of long-term antiretroviral therapy (ART). One additional 
patient in the standard-care group is known to have died 
after November 7, 2010 (a patient in Johannesburg, 
who died in January 2011). HIV denotes human immu-
nodeficiency virus.
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371 Underwent randomization
429 Participants were screened
58 Were excluded
15 Did not meet definition of primary 
HIV infection
19 Met other protocol exclusion criteria
24 Had other reasons
124 Were assigned to receive
48-wk ART
1 Was excluded owing 
to lack of evidence of
recent seroconversion
123 Were included in analysis
124 Were assigned to receive
standard care
123 Were included in analysis
1 Was excluded owing
to lack of evidence of
recent seroconversion
123 Were assigned to receive
12-wk ART
3 Were excluded
1 Did not have evi-
dence of recent
seroconversion
1 Was HIV-negative
at randomization
1 Underwent randomi-
zation in error
1 Died before reaching primary
end point
105 Had known primary end point
on Nov. 7, 2010
75 Reached primary end point
(2 died subsequently)
30 Did not reach primary end
point
17 Had unknown primary end
point status on Nov. 7, 2010
12 Were last assessed ≤1 mo
earlier
1 Was last assessed >1 to 
6 mo earlier
2 Were last assessed >6 to
≤18 mo earlier
2 Were last assessed >18 mo
earlier
2 Died before reaching primary
end point
107 Had known primary end point
on Nov. 7, 2010
73 Reached primary end point
(1 died subsequently)
34 Did not reach primary end
point
11 Had unknown primary end
point status on Nov. 7, 2010
4 Were last assessed ≤1 mo
earlier
1 Was last assessed >1 to 
6 mo earlier
1 Was last assessed >6 to
≤18 mo earlier
5 Were last assessed >18 mo
earlier
0 Died before reaching primary
end point
105 Had known primary end point
on Nov. 7, 2010
61 Reached primary end point
(2 died subsequently)
44 Did not reach primary end
point
18 Had unknown primary end
point status on Nov. 7, 2010
10 Were last assessed ≤1 mo
earlier
2 Were last assessed >1 to 
6 mo earlier
2 Were last assessed >6 to
≤18 mo earlier
4 Were last assessed >18 mo
earlier
 
120 Were included in analysis
5 Did not start ART
during primary HIV 
infection
3 Had concerns about
side effects
2 Chose not to start
118 Started ART during primary
HIV infection
120 Started ART during primary
HIV infection
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treatment effect on the time to the primary end 
point according to viral subtype (P = 0.56).
In a post hoc analysis, there was a trend to-
ward a greater effect of 48-week ART, as com-
pared with standard care, the sooner that random-
ization occurred after seroconversion (P = 0.09). 
For example, the hazard ratio for the primary 
end point was 0.41 (95% CI, 0.22 to 0.77) for an 
interval of 4 weeks between seroconversion and 
randomization, 0.65 (95% CI, 0.46 to 0.92) for 
an interval of 12 weeks, and 1.28 (95% CI, 0.54 to 
3.05) for an interval of 24 weeks. Median times 
to the primary end point among participants 
who had seroconversion 12 weeks or less before 
randomization were 218 weeks in the 48-week 
ART group (95% CI, 183 to ∞), 181 weeks in the 
12-week ART group (95% CI, 115 to 275), and 
126 weeks in the standard-care group (95% CI, 
Table 1. Baseline Characteristics of the 366 Eligible Participants Enrolled in the Trial.*
Characteristic
Standard Care
(N = 123)
12-Week ART
(N = 120)
48-Week ART
(N = 123)
Total
(N = 366)
Sex — no. (%)
Male 74 (60) 71 (59) 74 (60) 219 (60)
Female 49 (40) 49 (41) 49 (40) 147 (40)
Age — yr
Median (interquartile range) 31 (25–39) 32 (24–39) 33 (26–41) 32 (25–40)
Range 19–63 19–61 20–61 19–63
Evidence of seroconversion — no. (%)†
Definitive: criterion 1 or 2 86 (70) 85 (71) 84 (68) 255 (70)
Presumptive: criterion 3, 4, or 5 37 (30) 35 (29) 39 (32) 111 (30)
Estimated time since seroconversion at ran-
domization — wk‡
Median (interquartile range) 11 (8–15) 12 (9–15) 12 (9–15) 12 (9–15)
Range 2–24 1–23 1–22 1–24
CD4+ count — cells/mm3
Median (interquartile range)§ 543 (404–715) 519 (433–638) 605 (463–750) 559 (435–700)
Range 130–1226 95–1243 195–1399 95–1399
HIV RNA level — copies/ml
Median (interquartile range) 4.70 (3.68–5.24) 4.39 (3.59–5.18) 4.43 (3.81–5.13) 4.53 (3.67–5.18)
Range 1.70–6.22 1.40–6.22 2.22–6.47 1.40–6.47
Any drug resistance at Stanford level 4 or 5  
— no. (%)¶
8 (7) 5 (4) 8 (7) 21 (6)
Reported HIV seroconversion–type illness  
— no. (%)
81 (66) 64 (53) 70 (57) 215 (59)
* Characteristics were compared across randomized groups with the use of the Kruskal–Wallis test for medians and the 
chi-square test for categorical variables. None of these characteristics differed significantly among the three groups 
(P>0.05 for all comparisons), unless otherwise noted. ART denotes antiretroviral therapy, and HIV human immunodefi-
ciency virus.
† Primary HIV infection was defined as infection meeting one or more of the following criteria: a positive HIV-antibody 
test within 6 months after a negative test (criterion 1), a negative HIV-antibody test with a positive reverse-transcription–
polymerase-chain-reaction assay for HIV RNA (criterion 2), a low level of HIV antibodies (optical density units [OD], 
<0.6) according to a serologic testing algorithm for recent infection (subtype B strain only)18 (criterion 3), an equivocal 
HIV-antibody test with a repeat test within 2 weeks showing an increase in the level of HIV antibodies (criterion 4), or 
clinical manifestations of symptomatic HIV seroconversion illness supported by antigen positivity and less than 4 posi-
tive bands on Western blot analysis (criterion 5).
‡ The time of seroconversion was estimated as the midpoint between the most recent negative or equivocal test and the 
first positive test for patients who met criterion 1 or 4; as the date of the test for patients who met criterion 2, 3 (if OD 
≤0.01), or 5; and as the date of the test − [(OD × 150) ÷ 2] days for patients who met criterion 3 if the antibody level was 
greater than 0.01 OD.
§ P<0.05 (but P>0.01) for the overall comparison among the three groups.
¶ Levels range from 1 to 5, with a higher level indicating a greater degree of resistance. Data were not available for 1 par-
ticipant in the 12-week ART group (the HIV RNA value was too low) and 1 participant in the 48-week ART group (no 
sample was available).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SUSSEX on July 5, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Short-Course ART in Primary HIV Infection
n engl j med 368;3 nejm.org january 17, 2013 213
74 to 171), as compared with 229 weeks (95% CI, 
151 to ∞), 185 weeks (95% CI, 138 to 241), and 
213 weeks (95% CI, 123 to ∞), respectively, 
among those with seroconversion more than 12 
weeks before randomization (Fig. 2D).
In participants who started long-term ART, 
CD4+ counts at initiation tended to be higher in 
the 48-week ART group than in the 12-week 
ART and standard-care groups (median, 335 cells 
per cubic millimeter [interquartile range, 260 to 
440] vs. 314 cells per cubic millimeter [interquar-
tile range, 236 to 378] and 270 cells per cubic 
millimeter [interquartile range, 220 to 349], re-
spectively; P = 0.33 for the comparison with 12-
week ART and P=0.02 for the comparison with 
standard care, by the Wilcoxon rank-sum test). 
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Figure 2. Time from Randomization to End Points According to Study Group.
Panels A and D show data for the primary end point, and Panels B and C show data for the individual components of the primary end point. 
Primary HIV infection was defined as infection meeting one or more of the following criteria: a positive HIV-antibody test within 6 months 
after a negative test (criterion 1), a negative HIV-antibody test with a positive reverse-transcription–polymerase-chain-reaction assay for 
HIV RNA (criterion 2), a low level of HIV antibodies (optical density units [OD], <0.6) according to a serologic testing algorithm for recent 
infection (subtype B strain only)18 (criterion 3), an equivocal HIV-antibody test with a repeat test within 2 weeks showing an increase in 
the level of HIV antibodies (criterion 4), or clinical manifestations of symptomatic HIV seroconversion illness supported by antigen posi-
tivity and less than 4 positive bands on Western blot analysis (criterion 5). The time of seroconversion was estimated as the midpoint 
between the most recent negative or equivocal test and the first positive test for patients who met criterion 1 or 4; as the date of the test 
for patients who met criterion 2, 3 (if OD ≤0.01), or 5; and as the date of the test − [(OD × 150) ÷ 2] days for patients who met criterion 3 if 
the antibody level was greater than 0.01 OD.
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This finding may be related to the calendar 
times of initiation (median, January 2009 in the 
48-week ART group, July 2008 in the 12-week 
ART group, and May 2008 in the standard-care 
group), because a change in the treatment guide-
lines during the period of follow-up favored the 
initiation of long-term ART at a higher CD4+ 
count.26-28 Of the 172 participants who started 
long-term ART, 21 (12%) switched to second-line 
ART during follow-up.
Secondary End Points
Nineteen participants received a diagnosis of 
AIDS (6 in the 48-week ART group, 7 in the 12-
week ART group, and 6 in the standard-care 
group), and 8 participants died (2 in the 48-week 
ART group, 3 in the 12-week ART group, and 3 in 
the standard-care group) (see the Supplementary 
Appendix, available at NEJM.org). For the com-
posite of the primary end point, AIDS, or death, 
hazard ratios were very similar to the hazard ra-
tio for the primary end point.
The proportions of participants with a positive 
CD4+-specific response at week 60, among the 
108 participants for whom this information was 
available, were 75% in the 48-week ART group, 
78% in the 12-week ART group, and 51% in the 
standard-care group (P = 0.04 for 48-week ART vs. 
standard care and P = 0.02 for 12-week ART vs. 
standard care). Corresponding values for CD8+-
specific responses among 142 participants were 
80%, 89%, and 87% (P = 0.32 for 48-week ART 
vs. standard care and P = 0.78 for 12-week ART vs. 
standard care).
There was no significant difference in the 
decline in the CD4+ count from 24 weeks after 
completion of the short-course regimen in the 
treatment groups as compared with the decline 
from randomization in the standard-care group 
(on a square-root scale per 12 weeks: −0.37 cells 
per cubic millimeter in the 48-week ART group 
[95% CI, −0.43 to −0.30], −0.29 cells per cubic 
millimeter in the 12-week ART group [95% CI, 
−0.36 to −0.23], and −0.30 cells per cubic mil-
limeter in the standard-care group [95% CI, 
−0.35 to −0.24]; P = 0.12 for 48-week ART vs. 
standard care and P = 0.97 for 12-week ART vs. 
standard care) (Fig. 3A).
The mean change from baseline in the HIV 
RNA level at 36 weeks after completion of the 
12-week course of ART was similar to that at 
the same time point from randomization in the 
standard-care group (difference, −0.12 log10 cop-
ies per milliliter [95% CI, −0.32 to 0.07]). How-
ever, the mean change was significantly greater 
in the 48-week ART group than in the standard-
care group (difference, −0.44 log10 copies per 
milliliter [95% CI, −0.64 to −0.25]), and the dif-
ference was sustained at 60 weeks (Fig. 3B).
Of the 339 participants for whom an evalua-
tion of new drug-resistance mutations was avail-
able, 6 had resistance at Stanford level 4 or 5 
(range, 1 to 5, with a higher level indicating a 
greater degree of resistance) by week 120 (3 in 
the 48-week ART group, 1 in the 12-week ART 
group, and 2 in the standard-care group). Of 
these 6 participants, 5 had NNRTI-associated 
mutations (2 in the 48-week ART group, 2 in the 
12-week ART group, and 1 in the standard-care 
group) and 1 (in the 48-week ART group) had a 
protease inhibitor–associated mutation (46I mu-
tation).
Adverse Events
A total of 139 serious adverse events were reported 
in 93 participants (109 events required hospital-
ization or resulted in prolonged hospitalization, 
12 were life-threatening, 8 were fatal, 3 were non-
AIDS cancers, and 7 were other medical condi-
tions) (see the Supplementary Appendix), and 345 
grade 3 or 4 adverse events were reported in 165 
participants, with similar rates across the groups.
CD4+ Counts and HIV RNA after Initiation  
of Long-Term ART
Of the 172 participants who started long-term 
ART, 36 (21%) had virologic failure, with no evi-
dence of a significant difference between groups 
(hazard ratio, 0.73 for 48-week ART vs. standard 
care [95% CI, 0.31 to 1.72] and 0.91 for 12-week 
ART vs. standard care [95% CI, 0.42 to 1.99]). 
Increases in CD4+ counts after initiation of long-
term ART were similar across the three groups, 
although slightly steeper in the 48-week ART 
group (after 12 weeks, on a square-root scale per 
12 weeks: 0.39 cells per cubic millimeter in the 
48-week ART group [95% CI, 0.23 to 0.54], 0.21 
cells per cubic millimeter in the 12-week ART 
group [95% CI, 0.09 to 0.33], and 0.23 cells per 
cubic millimeter in the standard-care group [95% 
CI, 0.13 to 0.34]) (Fig. 4).
Overall Experience
Over the period of the trial, the average CD4+ 
count was higher by 138 cells per cubic millime-
ter (95% CI, 90 to 185) in the 48-week ART group 
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than in the standard-care group, and the average 
HIV RNA level was lower by 0.40 log10 copies per 
milliliter (95% CI, 0.20 to 0.61). The average 
CD4+ count was 649 cells per cubic millimeter in 
the 48-week ART group (95% CI, 616 to 683), 534 
cells per cubic millimeter in the 12-week ART 
group (95% CI, 500 to 568), and 512 cells per 
cubic millimeter in the standard-care group (95% 
CI, 479 to 545); the HIV RNA level was 3.23 log10 
copies per milliliter (95% CI, 3.08 to 3.37), 3.53 
log10 copies per milliliter (95% CI, 3.38 to 3.68), 
and 3.63 log10 copies per milliliter (95% CI, 3.49 
to 3.78), respectively. The average duration of 
ART during the median 4.2 years of follow-up 
was 1.5 years, 1.2 years, and 1.1 years, respec-
tively.
Discussion
The SPARTAC trial, which involved men and 
women from disparate settings in eight countries, 
assessed the efficacy of short-course ART during 
primary HIV infection. Our choice of a clinically 
relevant primary end point with several years of 
follow-up (median, >4 years) allowed an evalua-
tion of the effect of ART given during primary 
infection on disease progression, as compared 
with the current standard of care of no treat-
ment. A 48-week course of ART during primary 
HIV infection delayed disease progression and 
the consequent need for long-term ART, although 
the delay was not significantly longer than the du-
ration of initial treatment. We found no benefit of 
12-week ART given during primary HIV infection.
The trial was designed pragmatically to in-
clude persons in whom seroconversion had oc-
curred within 6 months before randomization, 
although we found that in the group receiving 
standard care, participants who underwent ran-
domization within 12 weeks after seroconversion 
had more rapid disease progression than those 
with a longer interval between seroconversion 
and randomization, a finding consistent with 
findings from a large observational study.24 Post 
hoc analyses identified a greater benefit of 48-
week ART for participants who received therapy 
closer to seroconversion, supporting findings 
from other studies.15,29 Future research focusing 
on patients with acute infection (seroconversion 
within the previous 12 weeks), a challenging 
group to identify, would be required to confirm 
this observation.
Observational studies have suggested that ART 
given during primary HIV infection could confer 
a durable beneficial effect by limiting HIV-medi-
ated immunologic damage,10,30-33 which was the 
main hypothesis underpinning our trial. Al-
though there was a significant increase in HIV-
specific responses with 48-week ART, as com-
pared with standard care, there also appeared to 
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Figure 3. Changes in the CD4+ Count and HIV RNA Level.
Panel A shows the output from the statistical model for the decline in the 
CD4+ count from 24 weeks after completion of the study regimen in the  
48-week and 12-week ART groups and from randomization in the standard-
care group. Panel B shows the differences from baseline in HIV RNA levels 
at 12, 24, 36, 48, and 60 weeks after completion of the study regimen in the 
48-week and 12-week ART groups and from randomization in the standard-
care group, with adjustment for the baseline value. Some measurements 
were censored owing to initiation of long-term ART. I bars indicate 95% 
confidence intervals.
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be a similar increase with 12-week ART. This 
finding was at odds with the main trial results, 
as were the results of the CD8+-specific respons-
es. It would therefore appear that the observed 
effects of short-course ART during primary HIV 
infection are not mediated through HIV-specific 
immunity, as determined by the frequency of 
positive ELISpot tests.
The higher overall average CD4+ count with 
48-week ART than with standard care is encour-
aging and may confer a clinical benefit. The sus-
tained CD4+ benefit after completion of a short 
course of ART in patients with primary HIV in-
fection contrasts with the findings in studies 
involving patients with chronic infection, which 
have shown a blunted CD4+ response when 
long-term ART is interrupted.34 Whether the 
lower HIV RNA levels after cessation of 48-week 
ART or the improved CD4+ recovery after initia-
tion of long-term ART can be maintained and 
will translate into a clinical benefit in the years 
ahead requires longer follow-up, which is 
planned.
Drug-resistant mutations developed in six 
participants by week 120. In five of these par-
ticipants, the mutations were most likely in-
duced by long-term ART (NNRTI mutations). 
One case of drug resistance was probably in-
duced by the short-course ART (46I mutation).
In summary, we found that a 48-week course 
of ART during primary HIV infection delayed a 
decline in the CD4+ count to less than 350 cells 
per cubic millimeter or the initiation of long-
term ART, but this delay was not significantly 
longer than the 48-week treatment period. How-
ever, our finding that, with the use of a realistic, 
clinically relevant definition of primary HIV in-
fection, 48 weeks of ART altered the course of 
the two main markers of HIV disease progres-
sion — namely, the CD4+ count and the HIV 
RNA level — beyond the treatment period is an 
intriguing observation that requires further eval-
uation. For maximal individual benefit, future 
studies that examine longer courses of therapy, 
therapy initiated earlier in primary HIV infec-
tion, or both may be required.
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